The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
11/26/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
RFA-PS-13-001
Opportunity Category:
Discretionary
Posted Date:
Nov 26, 2012
Creation Date:
Nov 26, 2012
Original Closing Date for Applications:
Jan 14, 2013
Current Closing Date for Applications:
Jan 14, 2013
Archive Date:
Feb 13, 2013
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Health
Category Explanation:
Expected Number of Awards:
1
Estimated Total Program Funding:
$1,500,000
Award Ceiling:
$300,000
Award Floor:
$100,000
CFDA Number(s):
93.270
--
Adult Viral Hepatitis Prevention and Control
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Native American tribal governments (Federally recognized)
Additional Information on Eligibility:
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for HHS/CDC support.
Agency Name
Centers for Disease Control and Prevention
Description
The Natural History and Prevention of Viral Hepatitis Among Alaska Native Persons FOA has two principal aims: 1) to improve efforts to prevent hepatitis A and B through vaccination and 2) to study interventions to reduce mortality and morbidity from chronic hepatitis B and C.
